Historically, fibrolamellar carcinoma (FLC) was considered a variant of conventional HCC, though the identification of a canonical chimeric fusion (DNAJB1-PRKACA) in FLC as well as differences in histology and clinical presentation have led to the acceptance of FLC as a distinct entity [9,10]. This evidence concerns the gene DNAJB1 and fibrolamellar hepatocellular carcinoma.